Aridis Pharmaceuticals Inc expected to post a loss of 63 cents a share - Earnings Preview

Aridis Pharmaceuticals

11/08/2021 03:54

* Aridis Pharmaceuticals Inc  ARDS.OQ   ARDS.O  is expected
to show a fall in quarterly revenue when it reports results on
August 11 (estimated). 
* The Los Gatos, California-based company is expected to report 
 a 70.0% decrease in revenue to $300 thousand from $1 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Aridis Pharmaceuticals
Inc is for a loss of 63 cents per share. For the same quarter
last year, the company reported a loss of 47 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $18.5​, about 77.4% above​ its last
closing price of $4.19. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.61       -0.62      -0.77     Missed  -24.7
 Dec. 31 2020              -0.59      -0.59     Met     0.6
 Sep. 30 2020  -0.64       -0.63      -0.65     Missed  -3.5​
 Jun. 30 2020  -0.74       -0.74      -0.47     Beat    36.8
 Mar.          -0.66​      -0.67      -0.73     Missed  -9​
 31​ 2020​                                              
 Dec. 31 2019  -0.77       -0.81      -0.63     Beat    22​
 Sep. 30 2019  -0.55       -0.33      -0.87     Missed  -163.6
 Jun. 30 2019  -0.84       -0.84      -1.03     Missed  -21.9
 This summary was machine generated August 11 at 02:54 GMT.  All
figures in US dollars unless otherwise stated